Molloy, Mark - Macquarie University - Department of Chemistry and Biomolecular Sciences

个人简介

Mark is a biochemist with 20 years' experience in proteomics. He completed his post-doctoral training at the University of Michigan Medical School. Later he worked in the proteomics R & D group at Pfizer, leading a team to identify biomarkers of new drug entities. He is Director of the Australian Proteome Analysis Facility, and interim Head of Chemistry and Biomolecular Sciences.

研究领域

My lab uses proteomic technologies for cancer research. Our research sits at the interface of biochemistry/cell biology/analytical chemistry/clinical chemistry. We have collaborators in clinical medicine, organic chemistry and molecular cell biology. Quantitative mass spectrometry techniques are heavily used in my group, but other important bioanalytical techniques including electrophoresis and chromatography are also applied. Most of my research utilises the state-of-the-art infrastructure located within the Australian Proteome Analysis Facility (APAF) at Macquarie University.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Meex RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, Goode RJ, Kingwell BA, Kraakman MJ, Febbraio MA, Greve JW, Rensen SS, Molloy MP, Lancaster GI, Bruce CR, Watt MJ. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab. 2015 Oct 20. pii: S1550-4131(15)00480-5. Penesyan A, Kumar SS, Kamath K, Shathili AM, Venkatakrishnan V, Krisp C, Packer NH, Molloy MP, Paulsen IT. Genetically and phenotypically distinct Pseudomonas aeruginosa cystic fibrosis isolates share a core proteomic signature. PLOS One 2015 10(10):e0138527. Percy, A. J.; Tamura-Wells, J.; Albar, J. P.; Aloria, K.; Amirkhani, A.; Araujo, G. D. T.; Arizmendi, J. M.; Blanco, F. J.; Canals, F.; Cho, J.-Y.; Colomé-Calls, N.; Corrales, F. J.; Domont, G.; Espadas, G.; Fernandez-Puente, P.; Gil, C.; Haynes, P. A.; Hernáez, M. L.; Kim, J. Y.; Kopylov, A.; Marcilla, M.; McKay, M. J.; Mirzaei, M.; Molloy, M. P.; Ohlund, L. B.; Paik, Y.-K.; Paradela, A.; Raftery, M.; Sabidó, E.; Sleno, L.; Wilffert, D.; Wolters, J. C.; Yoo, J. S.; Zgoda, V.; Parker, C. E.; Borchers, C. H., Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment. EuPA Open Proteomics 2015, 8, 6-15. Krisp C, Yang H, van Soest R, Molloy MP. Online peptide fractionation using a multiphasic microfluidic LC chip improves reproducibility and detection limits for quantitation in discovery and targeted proteomics. Mol. Cell Proteomics 2015, 14:1708-1719. Parker R, Vella L, Xavier D, Amirkhani A, Parker J, Cebon J, Molloy M. Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma. Front. Oncol. 2015, 5:95. doi: 10.3389/fonc.2015.00095. Martinez-Aguilar J, Clifton-Bligh R, Molloy MP. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer 2015, 15:199 doi:10.1186/s12885-015-1217-x Mahon, K., Lin, H-M., Castillo, L., Lee, B., Lee-Ng, M., Chatfield, M., Chiam, K., Breit,S., Brown, D., Marx, G., Molloy, MP, Pavlakis, N., Boyer, M., Stockler, MR., Daly, R.J., Henshall, S., Horvath, L. Cytokine profiling of docetaxel-resistant castration resistant prostate cancer. Br. J. Cancer 2015, 112, 1340–1348. Lin, C-H., Chik, J., Packer, NH., Molloy, M.P. Multi-dimensional fractionation is a requirement for quantitation of Golgi-resident glycosylation enzymes from cultured human cells. J. Proteome Res. 2015, 14, 747-55. Chik JH, Zhou J, Moh ES, Christopherson R, Clarke SJ, Molloy MP, Packer NH. Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. J. Proteomics. 2014, 108:146-62. Parker R, Clifton-Bligh R, Molloy MP. Phosphoproteomics of MAPK inhibition in BRAF mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition. Mol. Cancer Ther. 2014 13(7):1894-906.